1.4 Harmony 8: Once Weekly (QW) GLP1 Agonist Albiglutide (Albi) vs. Sitagliptin (Sita) in Type 2 Diabetes (T2D) Pts With Renal Impairment (RI): Week 26 Results (68-OR)

Emerging New Therapies for the Treatment of Type 2 Diabetes Mellitus: Glucagon-like Peptide-1 Receptor Agonists

“…In both drug-naive patients and in patients already taking medications for the treatment of type 2 diabetes, albiglutide effectively lowered HbA 1c levels to a greater extent compared with either placebo or other agents, including sitagliptin, glimepiride, and even the rapid-acting insulin lispro. [24][25][26][27][28][29]31 The lowering ability of HbA 1c seemed to be dose dependent, as albiglutide 50 mg produced greater reductions in HbA 1c compared with albiglutide 30 mg. 25 Albiglutide demonstrated noninferior HbA 1c reductions compared with insulin glargine. 27 Compared with pioglitazone (a peroxisome proliferator-activated receptor-γ agonist), albiglutide produced significantly fewer HbA 1c reductions but maintained the metabolic benefit of significant weight loss.…”

“…[24][25][26][27][28][29]31 The lowering ability of HbA 1c seemed to be dose dependent, as albiglutide 50 mg produced greater reductions in HbA 1c compared with albiglutide 30 mg. 25 Albiglutide demonstrated noninferior HbA 1c reductions compared with insulin glargine. 27 Compared with pioglitazone (a peroxisome proliferator-activated receptor-γ agonist), albiglutide produced significantly fewer HbA 1c reductions but maintained the metabolic benefit of significant weight loss. 28 The once-daily GLP-1 RA, liraglutide, was more effective than albiglutide but produced more nausea.…”

“…The treatment difference of 0.11% indicated noninferiority of albiglutide based on a prespecified noninferiority margin of 0.3% (P ¼ 0.0086). 27 Because weight increased in the insulin glargine group and decreased in the albiglutide group, change in weight was significantly different between the 2 groups (treatment difference, -2.61 kg; P o 0.0001). Symptomatic hypoglycemia occurred in both groups but was more common in patients receiving insulin glargine.…”

“…[24][25][26][27][28][29][30] In the HARMONY 1 trial, 310 patients undergoing a regimen of pioglitazone plus or minus metformin were assigned to receive albiglutide 30 mg QW or matching placebo and followed up for 52 weeks. 20 Albiglutide-treated patients achieved a significantly larger reduction from mean baseline HbA 1c at week 52 compared with placebo (-0.8% and -0.1%, respectively).…”

“…27 There were 486 patients randomly assigned to receive either albiglutide 30 mg (titrated to 50 mg based on glycemic response) QW or sitagliptin (dose based on renal function) once daily. At week 26, mean HbA 1c reductions were -0.83% and -0.52% in the albiglutide and sitagliptin groups, respectively (treatment difference, -0.31%; P ¼ 0.0003).…”